ASCOT trial pinpoints most efficient level of blood thinning treatment for hospitalized COVID-19 patients

The COVID-19 global pandemic remains a major public health challenge. ASCOT researchers aim to discover which treatments are most effective in patients hospitalized with COVID-19.

Related Keywords

United States ,Australia ,Monash ,South Australia ,Melbourne ,Victoria ,New Zealand ,India ,Nepal ,American ,Susan Morpeth ,Bala Venkatesh ,Zoe Mcquilten ,Emily Henderson ,Monash University ,American Society For Hematology ,Monash Health ,Doherty Institute ,Monash University Transfusion Research Unit Deputy ,American Society Of Hematology Annual Meeting Exposition ,George Institute For Global Health ,New England Journal ,Medicine Evidence ,American Society ,Investigator Professor Steven Tong ,Royal Melbourne Hospital ,Associate Professor Zoe Mcquilten ,Hematology Annual Meeting ,Discovery Industry Focus ,Professor Bala Venkatesh ,Professorial Fellow ,George Institute ,Global Health ,Clinical Microbiologist ,Infectious Diseases Physician ,Middlemore Hospital ,Blood ,Clinical Trial ,Covid 19 ,Hospital ,Infectious Diseases ,Pandemic ,Public Health ,Research ,